| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Isoflavones | 67 | 2025 | 132 | 8.060 |
Why?
|
| Soy Foods | 28 | 2025 | 60 | 4.680 |
Why?
|
| Mandibular Fractures | 5 | 2025 | 5 | 4.060 |
Why?
|
| Areca | 9 | 2024 | 33 | 3.820 |
Why?
|
| Fracture Fixation, Internal | 6 | 2025 | 13 | 3.230 |
Why?
|
| Mandibular Condyle | 4 | 2025 | 7 | 2.830 |
Why?
|
| Diet | 52 | 2025 | 826 | 2.570 |
Why?
|
| Chromatography, Liquid | 17 | 2024 | 182 | 2.570 |
Why?
|
| Mass Spectrometry | 14 | 2024 | 280 | 2.460 |
Why?
|
| Tocopherols | 17 | 2024 | 65 | 2.460 |
Why?
|
| Carotenoids | 19 | 2021 | 74 | 2.370 |
Why?
|
| Premenopause | 27 | 2021 | 110 | 2.270 |
Why?
|
| Alkaloids | 4 | 2022 | 46 | 2.220 |
Why?
|
| Chromatography, High Pressure Liquid | 17 | 2015 | 465 | 2.200 |
Why?
|
| Ubiquinone | 10 | 2021 | 23 | 2.180 |
Why?
|
| Arecoline | 3 | 2024 | 3 | 2.090 |
Why?
|
| Humans | 210 | 2026 | 43102 | 2.060 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2025 | 94 | 2.050 |
Why?
|
| Female | 175 | 2025 | 24698 | 1.990 |
Why?
|
| Cone-Beam Computed Tomography | 3 | 2025 | 17 | 1.970 |
Why?
|
| Middle Aged | 122 | 2025 | 12222 | 1.930 |
Why?
|
| Soybean Proteins | 22 | 2015 | 38 | 1.900 |
Why?
|
| Surgery, Oral | 3 | 2026 | 3 | 1.830 |
Why?
|
| Vitamin A | 11 | 2021 | 86 | 1.800 |
Why?
|
| Breast Neoplasms | 34 | 2025 | 1723 | 1.760 |
Why?
|
| Mouth Mucosa | 4 | 2024 | 30 | 1.750 |
Why?
|
| Bone Plates | 2 | 2025 | 4 | 1.750 |
Why?
|
| Saliva | 7 | 2019 | 119 | 1.720 |
Why?
|
| Nuts | 4 | 2024 | 10 | 1.680 |
Why?
|
| Postmenopause | 22 | 2025 | 141 | 1.660 |
Why?
|
| Adiposity | 13 | 2025 | 157 | 1.620 |
Why?
|
| Estrogens | 14 | 2019 | 203 | 1.610 |
Why?
|
| Aged | 87 | 2025 | 8214 | 1.600 |
Why?
|
| Adult | 95 | 2025 | 13872 | 1.570 |
Why?
|
| Case-Control Studies | 48 | 2025 | 1285 | 1.520 |
Why?
|
| Phenols | 8 | 2021 | 107 | 1.510 |
Why?
|
| Benzhydryl Compounds | 7 | 2021 | 50 | 1.510 |
Why?
|
| Male | 102 | 2025 | 23409 | 1.410 |
Why?
|
| Substance Abuse Detection | 3 | 2020 | 31 | 1.330 |
Why?
|
| Herbicides | 2 | 2021 | 43 | 1.300 |
Why?
|
| Phytoestrogens | 16 | 2022 | 39 | 1.200 |
Why?
|
| Oxytocin | 2 | 2020 | 24 | 1.190 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 6 | 2020 | 140 | 1.150 |
Why?
|
| Micronutrients | 10 | 2019 | 45 | 1.130 |
Why?
|
| Mandible | 3 | 2024 | 12 | 1.110 |
Why?
|
| Bone Screws | 2 | 2025 | 8 | 1.100 |
Why?
|
| Dietary Supplements | 15 | 2018 | 213 | 1.090 |
Why?
|
| Genistein | 15 | 2019 | 45 | 1.040 |
Why?
|
| Point-of-Care Systems | 4 | 2021 | 35 | 1.040 |
Why?
|
| Tandem Mass Spectrometry | 6 | 2020 | 241 | 1.030 |
Why?
|
| Calcium Phosphates | 2 | 2024 | 15 | 1.020 |
Why?
|
| Magnesium | 4 | 2025 | 94 | 1.010 |
Why?
|
| Cleft Lip | 1 | 2025 | 7 | 0.940 |
Why?
|
| Cleft Palate | 1 | 2025 | 9 | 0.940 |
Why?
|
| Facial Muscles | 1 | 2025 | 7 | 0.940 |
Why?
|
| Gonadal Steroid Hormones | 6 | 2025 | 55 | 0.930 |
Why?
|
| Maxillary Fractures | 1 | 2025 | 1 | 0.910 |
Why?
|
| Zygomatic Fractures | 1 | 2025 | 1 | 0.910 |
Why?
|
| Fetal Blood | 3 | 2013 | 48 | 0.870 |
Why?
|
| Intra-Abdominal Fat | 7 | 2024 | 46 | 0.870 |
Why?
|
| Vitamin D | 8 | 2018 | 196 | 0.850 |
Why?
|
| Jaw | 1 | 2024 | 20 | 0.850 |
Why?
|
| Cohort Studies | 32 | 2025 | 1759 | 0.830 |
Why?
|
| Lignans | 7 | 2022 | 22 | 0.830 |
Why?
|
| Environmental Pollutants | 5 | 2021 | 201 | 0.830 |
Why?
|
| Hawaii | 35 | 2021 | 2011 | 0.830 |
Why?
|
| Glycine | 2 | 2021 | 47 | 0.820 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2023 | 5 | 0.810 |
Why?
|
| Cross-Over Studies | 17 | 2021 | 115 | 0.810 |
Why?
|
| Prospective Studies | 29 | 2025 | 1600 | 0.810 |
Why?
|
| Diabetes Mellitus, Type 2 | 11 | 2021 | 760 | 0.780 |
Why?
|
| Steroids | 2 | 2014 | 45 | 0.780 |
Why?
|
| C-Reactive Protein | 14 | 2025 | 167 | 0.770 |
Why?
|
| Inflammation | 11 | 2025 | 758 | 0.760 |
Why?
|
| Urinalysis | 6 | 2016 | 34 | 0.750 |
Why?
|
| Young Adult | 16 | 2025 | 5080 | 0.730 |
Why?
|
| Nipple Aspirate Fluid | 5 | 2013 | 14 | 0.710 |
Why?
|
| Retrospective Studies | 7 | 2025 | 2544 | 0.710 |
Why?
|
| Reproducibility of Results | 14 | 2021 | 1081 | 0.700 |
Why?
|
| Risk Factors | 42 | 2024 | 3994 | 0.700 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2017 | 245 | 0.690 |
Why?
|
| Follow-Up Studies | 16 | 2025 | 1067 | 0.670 |
Why?
|
| Antioxidants | 10 | 2015 | 443 | 0.660 |
Why?
|
| Mastication | 5 | 2024 | 24 | 0.660 |
Why?
|
| Vitamins | 4 | 2021 | 81 | 0.660 |
Why?
|
| Cross-Sectional Studies | 19 | 2025 | 3156 | 0.660 |
Why?
|
| Flavonoids | 5 | 2018 | 100 | 0.650 |
Why?
|
| Adolescent | 21 | 2025 | 6081 | 0.630 |
Why?
|
| Body Fluids | 2 | 2018 | 19 | 0.620 |
Why?
|
| Patient Compliance | 5 | 2012 | 233 | 0.610 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2011 | 95 | 0.600 |
Why?
|
| Macaca fascicularis | 15 | 2015 | 65 | 0.600 |
Why?
|
| Limit of Detection | 5 | 2020 | 94 | 0.600 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 278 | 0.590 |
Why?
|
| Lipids | 8 | 2018 | 256 | 0.580 |
Why?
|
| Pilot Projects | 10 | 2021 | 760 | 0.580 |
Why?
|
| Phthalic Acids | 5 | 2021 | 18 | 0.580 |
Why?
|
| Anti-Bacterial Agents | 5 | 2011 | 432 | 0.570 |
Why?
|
| Breast | 6 | 2013 | 139 | 0.570 |
Why?
|
| Lung Neoplasms | 7 | 2024 | 495 | 0.560 |
Why?
|
| Treatment Outcome | 5 | 2025 | 1604 | 0.550 |
Why?
|
| Methylamines | 4 | 2021 | 14 | 0.550 |
Why?
|
| Infant | 8 | 2025 | 1175 | 0.520 |
Why?
|
| Body Mass Index | 19 | 2024 | 925 | 0.520 |
Why?
|
| Cerebral Ventricles | 2 | 2021 | 23 | 0.520 |
Why?
|
| Time Factors | 11 | 2019 | 1857 | 0.510 |
Why?
|
| Double-Blind Method | 13 | 2019 | 317 | 0.510 |
Why?
|
| Ultrasonography | 5 | 2025 | 135 | 0.510 |
Why?
|
| Fruit | 7 | 2021 | 178 | 0.500 |
Why?
|
| Cholecalciferol | 2 | 2013 | 20 | 0.490 |
Why?
|
| Nicotinic Acids | 1 | 2015 | 10 | 0.480 |
Why?
|
| Bacteria | 5 | 2021 | 293 | 0.470 |
Why?
|
| Environmental Monitoring | 2 | 2014 | 230 | 0.470 |
Why?
|
| gamma-Tocopherol | 6 | 2019 | 19 | 0.460 |
Why?
|
| Leptin | 8 | 2018 | 118 | 0.460 |
Why?
|
| Phytotherapy | 4 | 2009 | 75 | 0.460 |
Why?
|
| DNA Methylation | 2 | 2025 | 403 | 0.450 |
Why?
|
| Biological Availability | 7 | 2014 | 116 | 0.430 |
Why?
|
| Atherosclerosis | 7 | 2015 | 169 | 0.430 |
Why?
|
| Mouth Neoplasms | 1 | 2014 | 60 | 0.430 |
Why?
|
| Manikins | 2 | 2011 | 11 | 0.430 |
Why?
|
| Eating | 3 | 2016 | 167 | 0.430 |
Why?
|
| Soy Milk | 3 | 2009 | 6 | 0.420 |
Why?
|
| Cholesterol | 4 | 2020 | 232 | 0.410 |
Why?
|
| 4-Butyrolactone | 4 | 2021 | 13 | 0.410 |
Why?
|
| Milk | 2 | 2019 | 56 | 0.410 |
Why?
|
| Fatty Acids | 2 | 2012 | 134 | 0.410 |
Why?
|
| Dietary Proteins | 3 | 2009 | 35 | 0.400 |
Why?
|
| Vitamin D Deficiency | 3 | 2018 | 107 | 0.400 |
Why?
|
| Face | 2 | 2024 | 40 | 0.400 |
Why?
|
| Hydroxyestrones | 2 | 2012 | 8 | 0.400 |
Why?
|
| Mammography | 3 | 2012 | 212 | 0.390 |
Why?
|
| Obesity | 10 | 2023 | 1151 | 0.390 |
Why?
|
| Bone Cements | 2 | 2024 | 5 | 0.390 |
Why?
|
| Estradiol | 8 | 2019 | 268 | 0.380 |
Why?
|
| Kidney Failure, Chronic | 2 | 2006 | 242 | 0.380 |
Why?
|
| Colorectal Neoplasms | 6 | 2020 | 512 | 0.380 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2013 | 40 | 0.380 |
Why?
|
| Electrochemical Techniques | 2 | 2010 | 32 | 0.370 |
Why?
|
| Scopoletin | 2 | 2009 | 3 | 0.370 |
Why?
|
| Social Behavior | 3 | 2025 | 161 | 0.360 |
Why?
|
| Morinda | 2 | 2009 | 9 | 0.360 |
Why?
|
| Cardiovascular Diseases | 4 | 2021 | 749 | 0.360 |
Why?
|
| Intestines | 3 | 2012 | 71 | 0.360 |
Why?
|
| Adiponectin | 6 | 2025 | 59 | 0.360 |
Why?
|
| Nipples | 2 | 2011 | 20 | 0.360 |
Why?
|
| Food Analysis | 4 | 2016 | 34 | 0.350 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 2853 | 0.350 |
Why?
|
| Toxicology | 1 | 2011 | 8 | 0.350 |
Why?
|
| Nicotine | 5 | 2022 | 302 | 0.350 |
Why?
|
| Parabens | 2 | 2021 | 9 | 0.350 |
Why?
|
| Child | 11 | 2021 | 3443 | 0.350 |
Why?
|
| Ascorbic Acid | 2 | 2009 | 74 | 0.350 |
Why?
|
| Knowledge | 1 | 2011 | 16 | 0.350 |
Why?
|
| Intussusception | 1 | 2011 | 4 | 0.350 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2011 | 15 | 0.350 |
Why?
|
| Smoking | 10 | 2022 | 1024 | 0.340 |
Why?
|
| Early Diagnosis | 1 | 2011 | 68 | 0.340 |
Why?
|
| Puberty | 3 | 2013 | 31 | 0.340 |
Why?
|
| Estrone | 5 | 2019 | 21 | 0.330 |
Why?
|
| Appendicitis | 1 | 2010 | 18 | 0.330 |
Why?
|
| Beverages | 3 | 2006 | 66 | 0.330 |
Why?
|
| Solid Phase Extraction | 2 | 2020 | 13 | 0.330 |
Why?
|
| Catechin | 4 | 2015 | 39 | 0.320 |
Why?
|
| Anticarcinogenic Agents | 3 | 2012 | 77 | 0.320 |
Why?
|
| Erythrocytes | 1 | 2011 | 126 | 0.320 |
Why?
|
| Choline | 3 | 2021 | 61 | 0.320 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 25 | 0.320 |
Why?
|
| Cerebral Hemorrhage | 1 | 2011 | 104 | 0.320 |
Why?
|
| Patient Simulation | 1 | 2010 | 14 | 0.310 |
Why?
|
| Infant, Newborn | 3 | 2021 | 972 | 0.310 |
Why?
|
| Dehydroascorbic Acid | 1 | 2009 | 3 | 0.300 |
Why?
|
| Hair | 3 | 2019 | 38 | 0.300 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 14 | 0.300 |
Why?
|
| Nutritional Physiological Phenomena | 2 | 2011 | 36 | 0.300 |
Why?
|
| Students, Medical | 1 | 2011 | 158 | 0.290 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 611 | 0.290 |
Why?
|
| Uric Acid | 1 | 2009 | 29 | 0.290 |
Why?
|
| Computer Simulation | 1 | 2011 | 408 | 0.290 |
Why?
|
| Hydroxycholesterols | 3 | 2025 | 18 | 0.290 |
Why?
|
| Tea | 6 | 2012 | 46 | 0.290 |
Why?
|
| Estrogens, Non-Steroidal | 3 | 2002 | 20 | 0.280 |
Why?
|
| Body Weight | 5 | 2015 | 429 | 0.280 |
Why?
|
| F2-Isoprostanes | 4 | 2015 | 18 | 0.270 |
Why?
|
| Plant Preparations | 6 | 2008 | 24 | 0.270 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 139 | 0.270 |
Why?
|
| Animals | 30 | 2025 | 16992 | 0.270 |
Why?
|
| Poverty | 2 | 2021 | 400 | 0.270 |
Why?
|
| Hypercholesterolemia | 1 | 2007 | 42 | 0.270 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2007 | 39 | 0.260 |
Why?
|
| Vegetables | 6 | 2021 | 147 | 0.260 |
Why?
|
| Tocotrienols | 1 | 2007 | 2 | 0.260 |
Why?
|
| Cytochrome P-450 CYP1A2 | 3 | 2016 | 28 | 0.260 |
Why?
|
| Liver | 5 | 2021 | 511 | 0.260 |
Why?
|
| Child, Preschool | 6 | 2015 | 1546 | 0.260 |
Why?
|
| Lactation | 2 | 2020 | 44 | 0.250 |
Why?
|
| Lactalbumin | 4 | 2012 | 6 | 0.250 |
Why?
|
| Bone Density | 1 | 2007 | 103 | 0.250 |
Why?
|
| Infant Food | 1 | 2006 | 12 | 0.250 |
Why?
|
| Coronary Disease | 2 | 2021 | 123 | 0.250 |
Why?
|
| Caseins | 4 | 2012 | 15 | 0.250 |
Why?
|
| Tissue Scaffolds | 2 | 2024 | 35 | 0.250 |
Why?
|
| Acute-Phase Proteins | 1 | 2006 | 15 | 0.250 |
Why?
|
| Neoplasms | 4 | 2024 | 1377 | 0.250 |
Why?
|
| Japan | 9 | 2018 | 348 | 0.250 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2006 | 89 | 0.240 |
Why?
|
| Consent Forms | 1 | 2026 | 1 | 0.240 |
Why?
|
| Milk, Human | 1 | 2006 | 51 | 0.240 |
Why?
|
| Alloys | 1 | 2025 | 6 | 0.240 |
Why?
|
| Informed Consent | 1 | 2026 | 35 | 0.240 |
Why?
|
| Menstrual Cycle | 2 | 2004 | 36 | 0.230 |
Why?
|
| Prosthesis Design | 1 | 2025 | 47 | 0.230 |
Why?
|
| Citrus sinensis | 1 | 2005 | 4 | 0.230 |
Why?
|
| Prostatic Neoplasms | 5 | 2021 | 1092 | 0.230 |
Why?
|
| Radiography, Panoramic | 1 | 2025 | 3 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2024 | 587 | 0.220 |
Why?
|
| Testosterone | 6 | 2023 | 211 | 0.220 |
Why?
|
| Interleukin-6 | 5 | 2025 | 165 | 0.220 |
Why?
|
| Cognition | 3 | 2020 | 473 | 0.220 |
Why?
|
| Specimen Handling | 3 | 2011 | 63 | 0.220 |
Why?
|
| Robotics | 1 | 2025 | 43 | 0.220 |
Why?
|
| Imidazoles | 2 | 2016 | 142 | 0.220 |
Why?
|
| Women's Health | 3 | 2015 | 160 | 0.220 |
Why?
|
| Age Factors | 7 | 2014 | 1154 | 0.220 |
Why?
|
| Environmental Exposure | 3 | 2023 | 256 | 0.220 |
Why?
|
| Meat | 5 | 2016 | 46 | 0.210 |
Why?
|
| Oxidative Stress | 4 | 2015 | 1003 | 0.210 |
Why?
|
| Cephalometry | 1 | 2024 | 5 | 0.210 |
Why?
|
| Hesperidin | 2 | 2015 | 6 | 0.210 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 112 | 0.210 |
Why?
|
| Mothers | 1 | 2006 | 215 | 0.210 |
Why?
|
| Estriol | 2 | 2019 | 9 | 0.210 |
Why?
|
| Nutritional Status | 2 | 2018 | 119 | 0.210 |
Why?
|
| Osteonecrosis | 1 | 2023 | 8 | 0.200 |
Why?
|
| Estrogen Receptor beta | 3 | 2019 | 39 | 0.200 |
Why?
|
| Skull | 1 | 2023 | 28 | 0.200 |
Why?
|
| Ozone | 1 | 2023 | 26 | 0.200 |
Why?
|
| alpha-Tocopherol | 3 | 2014 | 27 | 0.200 |
Why?
|
| United States | 10 | 2021 | 5205 | 0.200 |
Why?
|
| Aging | 2 | 2010 | 783 | 0.190 |
Why?
|
| Nutrition Assessment | 3 | 2018 | 80 | 0.190 |
Why?
|
| Costs and Cost Analysis | 1 | 2022 | 60 | 0.190 |
Why?
|
| Genome-Wide Association Study | 2 | 2023 | 423 | 0.190 |
Why?
|
| Intestinal Mucosa | 2 | 2012 | 134 | 0.190 |
Why?
|
| Iliac Artery | 4 | 2015 | 8 | 0.190 |
Why?
|
| Isoprostanes | 2 | 2012 | 13 | 0.190 |
Why?
|
| Air Pollution | 1 | 2023 | 87 | 0.190 |
Why?
|
| Phenotype | 6 | 2025 | 780 | 0.180 |
Why?
|
| Renal Dialysis | 1 | 2003 | 131 | 0.180 |
Why?
|
| Calcium, Dietary | 2 | 2013 | 65 | 0.180 |
Why?
|
| Carcinogens | 3 | 2016 | 126 | 0.180 |
Why?
|
| Area Under Curve | 4 | 2018 | 95 | 0.180 |
Why?
|
| Sunlight | 3 | 2014 | 48 | 0.180 |
Why?
|
| Hormones | 1 | 2002 | 55 | 0.180 |
Why?
|
| Cholesterol, HDL | 4 | 2017 | 99 | 0.180 |
Why?
|
| Air Pollutants | 1 | 2023 | 130 | 0.180 |
Why?
|
| Administration, Oral | 5 | 2011 | 260 | 0.180 |
Why?
|
| Triclosan | 1 | 2021 | 5 | 0.180 |
Why?
|
| Mammary Glands, Animal | 3 | 2013 | 23 | 0.170 |
Why?
|
| Pancreas | 1 | 2021 | 45 | 0.170 |
Why?
|
| Risk Assessment | 6 | 2020 | 863 | 0.170 |
Why?
|
| Risk | 8 | 2021 | 287 | 0.170 |
Why?
|
| Molecular Structure | 3 | 2011 | 570 | 0.170 |
Why?
|
| Fibrin | 1 | 2021 | 10 | 0.170 |
Why?
|
| Metabolomics | 1 | 2021 | 95 | 0.170 |
Why?
|
| Receptors, Estrogen | 4 | 2025 | 183 | 0.170 |
Why?
|
| Emergency Medicine | 1 | 2021 | 33 | 0.170 |
Why?
|
| Progesterone | 3 | 2019 | 121 | 0.170 |
Why?
|
| Colon | 1 | 2002 | 120 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2002 | 165 | 0.170 |
Why?
|
| Carnitine | 1 | 2020 | 7 | 0.160 |
Why?
|
| Calcifediol | 3 | 2018 | 17 | 0.160 |
Why?
|
| Betaine | 1 | 2020 | 7 | 0.160 |
Why?
|
| China | 8 | 2022 | 229 | 0.160 |
Why?
|
| Alkylation | 1 | 2020 | 11 | 0.160 |
Why?
|
| Acetonitriles | 1 | 2020 | 10 | 0.160 |
Why?
|
| Tissue Engineering | 1 | 2021 | 75 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2019 | 1124 | 0.160 |
Why?
|
| Random Allocation | 6 | 2015 | 147 | 0.160 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2016 | 81 | 0.160 |
Why?
|
| Indicators and Reagents | 1 | 2020 | 61 | 0.160 |
Why?
|
| Adenoma | 2 | 2012 | 96 | 0.160 |
Why?
|
| Los Angeles | 6 | 2021 | 394 | 0.160 |
Why?
|
| Endometrial Neoplasms | 1 | 2021 | 79 | 0.160 |
Why?
|
| Actinobacteria | 1 | 2019 | 14 | 0.160 |
Why?
|
| Perimenopause | 1 | 2019 | 7 | 0.150 |
Why?
|
| Logistic Models | 7 | 2024 | 1009 | 0.150 |
Why?
|
| Blood Specimen Collection | 2 | 2010 | 12 | 0.150 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 223 | 0.150 |
Why?
|
| Clinical Competence | 2 | 2011 | 156 | 0.150 |
Why?
|
| Oxidation-Reduction | 2 | 2011 | 457 | 0.150 |
Why?
|
| Prognosis | 6 | 2021 | 861 | 0.150 |
Why?
|
| Pregnancy | 3 | 2013 | 1772 | 0.140 |
Why?
|
| Physicians | 1 | 2021 | 188 | 0.140 |
Why?
|
| Papillomavirus Infections | 3 | 2010 | 376 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 247 | 0.140 |
Why?
|
| Flavoring Agents | 1 | 2018 | 22 | 0.140 |
Why?
|
| Arylamine N-Acetyltransferase | 2 | 2012 | 26 | 0.140 |
Why?
|
| Intestinal Absorption | 3 | 2008 | 22 | 0.140 |
Why?
|
| Aldehydes | 1 | 2018 | 70 | 0.140 |
Why?
|
| Placebos | 3 | 2018 | 41 | 0.140 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2018 | 31 | 0.140 |
Why?
|
| Receptors, Progesterone | 4 | 2025 | 92 | 0.140 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2025 | 203 | 0.130 |
Why?
|
| Sex Hormone-Binding Globulin | 4 | 2025 | 25 | 0.130 |
Why?
|
| Meat Products | 1 | 2017 | 5 | 0.130 |
Why?
|
| Rats | 3 | 2021 | 3735 | 0.130 |
Why?
|
| Prevalence | 3 | 2018 | 1612 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2025 | 384 | 0.130 |
Why?
|
| Analysis of Variance | 2 | 2011 | 575 | 0.130 |
Why?
|
| Electrolytes | 1 | 2016 | 30 | 0.130 |
Why?
|
| Phospholipids | 1 | 2017 | 70 | 0.130 |
Why?
|
| Absorptiometry, Photon | 3 | 2018 | 76 | 0.120 |
Why?
|
| Minerals | 1 | 2016 | 53 | 0.120 |
Why?
|
| Kynurenic Acid | 1 | 2016 | 9 | 0.120 |
Why?
|
| Cholesterol, LDL | 2 | 2007 | 73 | 0.120 |
Why?
|
| Kynurenine | 1 | 2016 | 8 | 0.120 |
Why?
|
| Flavanones | 3 | 2018 | 15 | 0.120 |
Why?
|
| Histones | 2 | 2015 | 197 | 0.120 |
Why?
|
| Mitochondria | 1 | 2020 | 523 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2019 | 549 | 0.120 |
Why?
|
| Melanins | 1 | 2016 | 42 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 704 | 0.120 |
Why?
|
| Seasons | 2 | 2013 | 139 | 0.120 |
Why?
|
| Sleep | 1 | 2017 | 185 | 0.120 |
Why?
|
| Calcium Compounds | 1 | 2015 | 6 | 0.110 |
Why?
|
| Radiation, Ionizing | 1 | 2015 | 13 | 0.110 |
Why?
|
| Menthol | 1 | 2015 | 23 | 0.110 |
Why?
|
| Genitalia, Female | 2 | 2006 | 29 | 0.110 |
Why?
|
| Dansyl Compounds | 1 | 2014 | 7 | 0.110 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 201 | 0.110 |
Why?
|
| Picolinic Acids | 1 | 2014 | 12 | 0.110 |
Why?
|
| Radiation Injuries | 1 | 2015 | 23 | 0.110 |
Why?
|
| Lymphocytes | 2 | 2014 | 124 | 0.110 |
Why?
|
| Guam | 1 | 2015 | 83 | 0.110 |
Why?
|
| Cell Differentiation | 2 | 2021 | 638 | 0.110 |
Why?
|
| Endothelium | 1 | 2014 | 28 | 0.110 |
Why?
|
| Triglycerides | 3 | 2017 | 147 | 0.110 |
Why?
|
| Absorption | 1 | 2014 | 22 | 0.110 |
Why?
|
| Equipment Design | 1 | 2014 | 145 | 0.110 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2014 | 11 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 224 | 0.110 |
Why?
|
| Vagina | 2 | 2012 | 89 | 0.110 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 12 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 34 | 0.100 |
Why?
|
| Oxides | 1 | 2015 | 100 | 0.100 |
Why?
|
| Ubiquitination | 1 | 2014 | 62 | 0.100 |
Why?
|
| Vesicular Transport Proteins | 1 | 2014 | 48 | 0.100 |
Why?
|
| Feeding Behavior | 3 | 2009 | 469 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2015 | 458 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 1766 | 0.100 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2013 | 104 | 0.100 |
Why?
|
| Incidence | 4 | 2020 | 1078 | 0.100 |
Why?
|
| California | 4 | 2018 | 548 | 0.100 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 35 | 0.100 |
Why?
|
| Vitamin B 6 | 1 | 2012 | 7 | 0.100 |
Why?
|
| Abdominal Fat | 1 | 2012 | 21 | 0.100 |
Why?
|
| Erythrocyte Membrane | 1 | 2012 | 20 | 0.090 |
Why?
|
| Statistics, Nonparametric | 3 | 2009 | 113 | 0.090 |
Why?
|
| Emigrants and Immigrants | 1 | 2015 | 158 | 0.090 |
Why?
|
| Matrix Metalloproteinases | 1 | 2012 | 49 | 0.090 |
Why?
|
| Estrogen Antagonists | 1 | 2012 | 30 | 0.090 |
Why?
|
| Pregnanediol | 2 | 2019 | 4 | 0.090 |
Why?
|
| Selenium | 3 | 2009 | 155 | 0.090 |
Why?
|
| Diet Records | 4 | 2014 | 58 | 0.090 |
Why?
|
| Heterocyclic Compounds | 1 | 2012 | 23 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2014 | 243 | 0.090 |
Why?
|
| Cell Count | 1 | 2012 | 145 | 0.090 |
Why?
|
| Endometrium | 1 | 2012 | 59 | 0.090 |
Why?
|
| Coronary Vessels | 3 | 2008 | 92 | 0.090 |
Why?
|
| Ovariectomy | 5 | 2015 | 127 | 0.090 |
Why?
|
| DNA Damage | 1 | 2014 | 356 | 0.090 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 1234 | 0.090 |
Why?
|
| Mental Disorders | 1 | 2016 | 392 | 0.090 |
Why?
|
| Deoxyguanosine | 1 | 2011 | 36 | 0.090 |
Why?
|
| Hydrolysis | 1 | 2011 | 97 | 0.090 |
Why?
|
| Odds Ratio | 5 | 2014 | 587 | 0.090 |
Why?
|
| Stroke | 1 | 2015 | 340 | 0.090 |
Why?
|
| 25-Hydroxyvitamin D 2 | 3 | 2018 | 8 | 0.090 |
Why?
|
| Radiography | 1 | 2011 | 71 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2011 | 38 | 0.090 |
Why?
|
| Energy Intake | 2 | 2015 | 164 | 0.080 |
Why?
|
| Health Behavior | 1 | 2015 | 575 | 0.080 |
Why?
|
| Problem-Based Learning | 1 | 2011 | 42 | 0.080 |
Why?
|
| Glutathione Transferase | 1 | 2011 | 90 | 0.080 |
Why?
|
| Rectus Abdominis | 1 | 2010 | 2 | 0.080 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 74 | 0.080 |
Why?
|
| Anus Diseases | 1 | 2010 | 17 | 0.080 |
Why?
|
| Stereoisomerism | 1 | 2011 | 169 | 0.080 |
Why?
|
| Creatinine | 2 | 2012 | 102 | 0.080 |
Why?
|
| Medical Staff, Hospital | 1 | 2010 | 15 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 238 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2010 | 24 | 0.080 |
Why?
|
| Amides | 1 | 2011 | 71 | 0.080 |
Why?
|
| Milk Proteins | 1 | 2010 | 29 | 0.080 |
Why?
|
| Blood Glucose | 2 | 2014 | 389 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2021 | 934 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2012 | 375 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 179 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2013 | 434 | 0.080 |
Why?
|
| Unconsciousness | 1 | 2010 | 4 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 1070 | 0.080 |
Why?
|
| Anus Neoplasms | 1 | 2010 | 44 | 0.080 |
Why?
|
| Ovarian Follicle | 1 | 2010 | 44 | 0.080 |
Why?
|
| Anticholesteremic Agents | 2 | 2007 | 25 | 0.080 |
Why?
|
| Diet, Atherogenic | 4 | 2015 | 6 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2013 | 666 | 0.080 |
Why?
|
| Mental Recall | 3 | 2008 | 84 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 440 | 0.080 |
Why?
|
| Insulin | 2 | 2009 | 258 | 0.080 |
Why?
|
| Dairy Products | 2 | 2006 | 34 | 0.070 |
Why?
|
| Schools, Medical | 1 | 2011 | 208 | 0.070 |
Why?
|
| Nutritive Value | 1 | 2009 | 37 | 0.070 |
Why?
|
| Seaweed | 1 | 2009 | 14 | 0.070 |
Why?
|
| Parathyroid Hormone | 1 | 2009 | 41 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2006 | 27 | 0.070 |
Why?
|
| Cytokines | 1 | 2013 | 678 | 0.070 |
Why?
|
| Hyperlipoproteinemias | 1 | 2008 | 2 | 0.070 |
Why?
|
| Norpregnenes | 1 | 2008 | 2 | 0.070 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2008 | 19 | 0.070 |
Why?
|
| Nurses | 3 | 2015 | 55 | 0.070 |
Why?
|
| Self Concept | 1 | 2010 | 171 | 0.070 |
Why?
|
| Apolipoproteins E | 2 | 2012 | 138 | 0.070 |
Why?
|
| Glucose | 2 | 2021 | 244 | 0.070 |
Why?
|
| DNA | 1 | 2011 | 592 | 0.070 |
Why?
|
| Fatigue | 1 | 2009 | 100 | 0.070 |
Why?
|
| Fermentation | 1 | 2008 | 39 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 638 | 0.070 |
Why?
|
| Algorithms | 1 | 2011 | 509 | 0.070 |
Why?
|
| Plant Extracts | 2 | 2009 | 302 | 0.070 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2009 | 192 | 0.070 |
Why?
|
| Collagen Type I | 1 | 2007 | 35 | 0.070 |
Why?
|
| Tumor Virus Infections | 1 | 2007 | 22 | 0.070 |
Why?
|
| Alkaline Phosphatase | 1 | 2007 | 54 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 2007 | 44 | 0.060 |
Why?
|
| Cervix Uteri | 1 | 2007 | 48 | 0.060 |
Why?
|
| Linear Models | 2 | 2012 | 317 | 0.060 |
Why?
|
| Carotid Artery Diseases | 1 | 2007 | 26 | 0.060 |
Why?
|
| Peptides | 2 | 2007 | 372 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2008 | 259 | 0.060 |
Why?
|
| Food, Formulated | 1 | 2006 | 4 | 0.060 |
Why?
|
| Prealbumin | 1 | 2006 | 8 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 291 | 0.060 |
Why?
|
| Mice | 7 | 2019 | 6644 | 0.060 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2006 | 28 | 0.060 |
Why?
|
| Cattle | 2 | 2019 | 498 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 719 | 0.060 |
Why?
|
| Serum Albumin | 1 | 2006 | 59 | 0.060 |
Why?
|
| Testis | 1 | 2007 | 207 | 0.060 |
Why?
|
| Coronary Circulation | 1 | 2005 | 29 | 0.060 |
Why?
|
| Macaca mulatta | 1 | 2006 | 139 | 0.060 |
Why?
|
| Benzopyrans | 1 | 2006 | 25 | 0.060 |
Why?
|
| Comprehension | 1 | 2026 | 41 | 0.060 |
Why?
|
| Pain | 1 | 2009 | 290 | 0.060 |
Why?
|
| CpG Islands | 1 | 2025 | 109 | 0.060 |
Why?
|
| Regression Analysis | 3 | 2013 | 490 | 0.060 |
Why?
|
| Diabetic Nephropathies | 1 | 2006 | 78 | 0.060 |
Why?
|
| Brazil | 2 | 2016 | 84 | 0.060 |
Why?
|
| Folic Acid | 1 | 2005 | 49 | 0.060 |
Why?
|
| Apoptosis | 3 | 2014 | 1568 | 0.060 |
Why?
|
| Cotinine | 2 | 2015 | 44 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2025 | 74 | 0.060 |
Why?
|
| Breast Feeding | 1 | 2006 | 126 | 0.060 |
Why?
|
| Melanoma | 1 | 2006 | 110 | 0.050 |
Why?
|
| Dogs | 1 | 2025 | 204 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2005 | 83 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 234 | 0.050 |
Why?
|
| Globulins | 1 | 2004 | 3 | 0.050 |
Why?
|
| Cholesterol Esters | 1 | 2004 | 4 | 0.050 |
Why?
|
| Feces | 2 | 2021 | 132 | 0.050 |
Why?
|
| Body Composition | 2 | 2018 | 159 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 518 | 0.050 |
Why?
|
| Genitalia, Male | 1 | 2004 | 14 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 43 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 178 | 0.050 |
Why?
|
| Quality of Life | 1 | 2009 | 616 | 0.050 |
Why?
|
| Glucosides | 1 | 2004 | 21 | 0.050 |
Why?
|
| Cross-Cultural Comparison | 1 | 2004 | 111 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2010 | 734 | 0.050 |
Why?
|
| Thailand | 1 | 2003 | 51 | 0.050 |
Why?
|
| Philippines | 2 | 2015 | 81 | 0.050 |
Why?
|
| Fibroadenoma | 1 | 2003 | 4 | 0.050 |
Why?
|
| Chromans | 1 | 2003 | 16 | 0.050 |
Why?
|
| Nitrogen Dioxide | 1 | 2023 | 17 | 0.050 |
Why?
|
| Benzene | 1 | 2023 | 17 | 0.050 |
Why?
|
| Vehicle Emissions | 1 | 2023 | 22 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2009 | 502 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2015 | 1596 | 0.050 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2002 | 19 | 0.050 |
Why?
|
| Onions | 1 | 2002 | 10 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 291 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2004 | 142 | 0.050 |
Why?
|
| Calibration | 1 | 2002 | 63 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2023 | 83 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2021 | 863 | 0.050 |
Why?
|
| Wine | 1 | 2002 | 9 | 0.050 |
Why?
|
| Luteinizing Hormone | 1 | 2002 | 61 | 0.050 |
Why?
|
| Citrus | 1 | 2002 | 14 | 0.050 |
Why?
|
| Longitudinal Studies | 3 | 2013 | 1063 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2002 | 43 | 0.050 |
Why?
|
| Apolipoproteins B | 1 | 2002 | 18 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2023 | 180 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2021 | 9 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2021 | 5 | 0.040 |
Why?
|
| HIV Infections | 1 | 2016 | 2586 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2021 | 20 | 0.040 |
Why?
|
| Calcium | 2 | 2016 | 491 | 0.040 |
Why?
|
| Body Fat Distribution | 1 | 2021 | 26 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2002 | 127 | 0.040 |
Why?
|
| Rats, Inbred F344 | 1 | 2002 | 258 | 0.040 |
Why?
|
| Quinolines | 1 | 2002 | 78 | 0.040 |
Why?
|
| Korea | 2 | 2012 | 37 | 0.040 |
Why?
|
| Genotype | 3 | 2010 | 800 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 385 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2021 | 22 | 0.040 |
Why?
|
| Hydrocephalus | 1 | 2021 | 16 | 0.040 |
Why?
|
| Shellfish | 1 | 2020 | 14 | 0.040 |
Why?
|
| Southeastern United States | 1 | 2021 | 64 | 0.040 |
Why?
|
| Endotoxins | 1 | 2021 | 18 | 0.040 |
Why?
|
| Osteogenesis | 1 | 2021 | 57 | 0.040 |
Why?
|
| Disease Progression | 2 | 2015 | 667 | 0.040 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2021 | 72 | 0.040 |
Why?
|
| Hydrogels | 1 | 2021 | 59 | 0.040 |
Why?
|
| Lipase | 1 | 2020 | 20 | 0.040 |
Why?
|
| Metformin | 1 | 2021 | 75 | 0.040 |
Why?
|
| Prediabetic State | 1 | 2021 | 69 | 0.040 |
Why?
|
| Fishes | 1 | 2020 | 73 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2021 | 182 | 0.040 |
Why?
|
| Hot Flashes | 1 | 2019 | 8 | 0.040 |
Why?
|
| Biotransformation | 1 | 2019 | 69 | 0.040 |
Why?
|
| Fluorescence | 1 | 2020 | 118 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 74 | 0.040 |
Why?
|
| Magnesium Deficiency | 1 | 2018 | 2 | 0.040 |
Why?
|
| 24,25-Dihydroxyvitamin D 3 | 1 | 2018 | 3 | 0.040 |
Why?
|
| Ergocalciferols | 1 | 2018 | 6 | 0.040 |
Why?
|
| Species Specificity | 1 | 2019 | 286 | 0.040 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2004 | 367 | 0.040 |
Why?
|
| Calcitriol | 1 | 2018 | 32 | 0.040 |
Why?
|
| Lung | 1 | 2022 | 492 | 0.040 |
Why?
|
| Genome, Bacterial | 1 | 2019 | 139 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 652 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2014 | 116 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 332 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2013 | 1455 | 0.040 |
Why?
|
| Fructose | 1 | 2018 | 24 | 0.040 |
Why?
|
| Sucrose | 1 | 2018 | 33 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2019 | 117 | 0.040 |
Why?
|
| Anthropometry | 2 | 2012 | 97 | 0.040 |
Why?
|
| Androgens | 1 | 2019 | 106 | 0.040 |
Why?
|
| Mice, Inbred Strains | 2 | 2011 | 114 | 0.030 |
Why?
|
| Weight Gain | 1 | 2018 | 139 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2018 | 104 | 0.030 |
Why?
|
| Sex Factors | 2 | 2012 | 1028 | 0.030 |
Why?
|
| Animal Feed | 2 | 2009 | 53 | 0.030 |
Why?
|
| Cell Survival | 1 | 2021 | 945 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2010 | 311 | 0.030 |
Why?
|
| Diet, Mediterranean | 1 | 2017 | 37 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 87 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 2 | 2008 | 121 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2017 | 48 | 0.030 |
Why?
|
| Cell Movement | 1 | 2021 | 655 | 0.030 |
Why?
|
| Sulfates | 1 | 2016 | 26 | 0.030 |
Why?
|
| Phosphates | 1 | 2016 | 54 | 0.030 |
Why?
|
| Sodium | 1 | 2016 | 102 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2013 | 1271 | 0.030 |
Why?
|
| Potassium | 1 | 2016 | 109 | 0.030 |
Why?
|
| Kidney | 1 | 2018 | 372 | 0.030 |
Why?
|
| Uterus | 2 | 2006 | 52 | 0.030 |
Why?
|
| Phylogeny | 1 | 2019 | 769 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 42 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2012 | 1035 | 0.030 |
Why?
|
| Coumaric Acids | 1 | 2015 | 3 | 0.030 |
Why?
|
| Immunoassay | 1 | 2016 | 74 | 0.030 |
Why?
|
| Caffeic Acids | 1 | 2015 | 5 | 0.030 |
Why?
|
| Tokyo | 1 | 2015 | 5 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2017 | 201 | 0.030 |
Why?
|
| Organ Size | 2 | 2007 | 170 | 0.030 |
Why?
|
| Menopause, Premature | 1 | 2015 | 6 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 2015 | 47 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 163 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 282 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2015 | 40 | 0.030 |
Why?
|
| Quercetin | 1 | 2015 | 46 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 595 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2021 | 719 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2014 | 39 | 0.030 |
Why?
|
| Intracellular Membranes | 1 | 2014 | 36 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2014 | 37 | 0.030 |
Why?
|
| Permeability | 1 | 2014 | 67 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2014 | 33 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2006 | 158 | 0.030 |
Why?
|
| Biomimetic Materials | 1 | 2014 | 24 | 0.030 |
Why?
|
| Luteal Phase | 1 | 2013 | 6 | 0.030 |
Why?
|
| Reference Values | 1 | 2014 | 211 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2014 | 80 | 0.030 |
Why?
|
| Lysosomes | 1 | 2014 | 86 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 163 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 2 | 2006 | 139 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 153 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 114 | 0.020 |
Why?
|
| Alcohol Drinking | 2 | 2012 | 609 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 2676 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 91 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2014 | 118 | 0.020 |
Why?
|
| beta Carotene | 1 | 2012 | 11 | 0.020 |
Why?
|
| Lutein | 1 | 2012 | 6 | 0.020 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2012 | 6 | 0.020 |
Why?
|
| Xanthophylls | 1 | 2012 | 21 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2006 | 347 | 0.020 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2012 | 16 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 26 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 185 | 0.020 |
Why?
|
| Gene Expression | 2 | 2006 | 701 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 51 | 0.020 |
Why?
|
| Overweight | 1 | 2015 | 249 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2012 | 25 | 0.020 |
Why?
|
| SEER Program | 1 | 2013 | 164 | 0.020 |
Why?
|
| Memory | 1 | 2014 | 174 | 0.020 |
Why?
|
| Metagenome | 1 | 2012 | 31 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 162 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 368 | 0.020 |
Why?
|
| Amines | 1 | 2012 | 41 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 13 | 0.020 |
Why?
|
| Reproduction | 1 | 2012 | 94 | 0.020 |
Why?
|
| Health Surveys | 1 | 2013 | 405 | 0.020 |
Why?
|
| Infusions, Subcutaneous | 1 | 2011 | 1 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 70 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 290 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2011 | 37 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 508 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 138 | 0.020 |
Why?
|
| Uterine Cervical Diseases | 1 | 2010 | 14 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 118 | 0.020 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2010 | 5 | 0.020 |
Why?
|
| Androstenedione | 1 | 2010 | 19 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 269 | 0.020 |
Why?
|
| Alphapapillomavirus | 1 | 2010 | 31 | 0.020 |
Why?
|
| Anal Canal | 1 | 2010 | 32 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2010 | 9 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 835 | 0.020 |
Why?
|
| Protestantism | 1 | 2010 | 5 | 0.020 |
Why?
|
| Aromatase | 1 | 2010 | 20 | 0.020 |
Why?
|
| Fructosamine | 1 | 2009 | 2 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 114 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2010 | 206 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2009 | 75 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 95 | 0.020 |
Why?
|
| Hyperparathyroidism | 1 | 2009 | 5 | 0.020 |
Why?
|
| Social Dominance | 1 | 2008 | 6 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 195 | 0.020 |
Why?
|
| Reference Standards | 1 | 2008 | 55 | 0.020 |
Why?
|
| Freeze Drying | 1 | 2008 | 29 | 0.020 |
Why?
|
| Biopsy | 1 | 2008 | 177 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 195 | 0.020 |
Why?
|
| Sperm Count | 1 | 2007 | 28 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2008 | 452 | 0.020 |
Why?
|
| Laboratory Animal Science | 1 | 2006 | 1 | 0.020 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 2006 | 18 | 0.020 |
Why?
|
| Sunburn | 1 | 2006 | 5 | 0.020 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2006 | 29 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2006 | 38 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 43 | 0.020 |
Why?
|
| Nitroglycerin | 1 | 2005 | 7 | 0.020 |
Why?
|
| Diet, Protein-Restricted | 1 | 2005 | 6 | 0.020 |
Why?
|
| Pterocarpans | 1 | 2006 | 25 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2006 | 45 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 386 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 55 | 0.010 |
Why?
|
| Uterine Neoplasms | 1 | 2006 | 53 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 236 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 2157 | 0.010 |
Why?
|
| Seed Storage Proteins | 1 | 2004 | 1 | 0.010 |
Why?
|
| Antigens, Plant | 1 | 2004 | 3 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2006 | 346 | 0.010 |
Why?
|
| Receptors, LDL | 1 | 2004 | 42 | 0.010 |
Why?
|
| Diet Surveys | 1 | 2004 | 99 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 263 | 0.010 |
Why?
|
| Kanamycin | 1 | 2003 | 5 | 0.010 |
Why?
|
| Vancomycin | 1 | 2003 | 7 | 0.010 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2003 | 1 | 0.010 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2004 | 43 | 0.010 |
Why?
|
| Ethanol | 1 | 2006 | 224 | 0.010 |
Why?
|
| Metronidazole | 1 | 2003 | 16 | 0.010 |
Why?
|
| Doxycycline | 1 | 2003 | 32 | 0.010 |
Why?
|
| Menopause | 1 | 2003 | 64 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2006 | 358 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 123 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2002 | 24 | 0.010 |
Why?
|
| Dihydrotestosterone | 1 | 2002 | 28 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 52 | 0.010 |
Why?
|
| Cyclins | 1 | 2002 | 34 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2002 | 56 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2002 | 74 | 0.010 |
Why?
|
| Cholesterol, VLDL | 1 | 2002 | 4 | 0.010 |
Why?
|
| Apolipoprotein B-100 | 1 | 2002 | 7 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2004 | 258 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2002 | 69 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2002 | 64 | 0.010 |
Why?
|
| Receptors, Androgen | 1 | 2002 | 144 | 0.010 |
Why?
|
| Sexual Partners | 1 | 2004 | 326 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2002 | 220 | 0.010 |
Why?
|
| Registries | 1 | 2002 | 437 | 0.010 |
Why?
|